These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 10844007)

  • 1. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
    J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
    Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
    Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
    Dedeoglu A; Kubilus JK; Yang L; Ferrante KL; Hersch SM; Beal MF; Ferrante RJ
    J Neurochem; 2003 Jun; 85(6):1359-67. PubMed ID: 12787055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.
    Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
    Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.
    van Dellen A; Welch J; Dixon RM; Cordery P; York D; Styles P; Blakemore C; Hannan AJ
    Neuroreport; 2000 Nov; 11(17):3751-7. PubMed ID: 11117485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype.
    Kaemmerer WF; Rodrigues CM; Steer CJ; Low WC
    Neuroscience; 2001; 103(3):713-24. PubMed ID: 11274790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
    Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
    Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.
    Paldino E; Balducci C; La Vitola P; Artioli L; D'Angelo V; Giampà C; Artuso V; Forloni G; Fusco FR
    Mol Neurobiol; 2020 Apr; 57(4):1889-1903. PubMed ID: 31879858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of creatine.
    Beal MF
    Amino Acids; 2011 May; 40(5):1305-13. PubMed ID: 21448659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease.
    Ruskin DN; Ross JL; Kawamura M; Ruiz TL; Geiger JD; Masino SA
    Physiol Behav; 2011 Jul; 103(5):501-7. PubMed ID: 21501628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.
    Lerner RP; Trejo Martinez Ldel C; Zhu C; Chesselet MF; Hickey MA
    Brain Res Bull; 2012 Apr; 87(6):571-8. PubMed ID: 22326483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
    Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S
    J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
    Yang L; Calingasan NY; Wille EJ; Cormier K; Smith K; Ferrante RJ; Beal MF
    J Neurochem; 2009 Jun; 109(5):1427-39. PubMed ID: 19476553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.